India's Lupin in US marketing deal for Suprax
Indian drugmaker Lupin's US subsidiary has entered into a promotion agreement for Suprax (cefixime) 400mg tablets with ASCEND Therapeutics.
Under the terms of the alliance, ASCEND was set to initiate promotion of the product in the USA in the month of June. The US firm has a 50-person women's health sales force which will detail the product primarily to obstetricians and gynecologists. Lupin will continue to promote the agent to pediatricians and family practitioners.
The US antibiotic market for treatment of urinary tract infections is $450.0 million, and the OB/GYN area is among the top three physician specialties prescribing antibiotics for treatment of UTIs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze